$11.82+0.48 (+4.23%)
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
MiNK Therapeutics, Inc. in the Healthcare sector is trading at $11.82 with a market capitalization of $64M. Wall Street consensus targets $39.00 (2 analysts), implying a +229.9% move over the next 12 months. The stock is currently near its 52-week low of $6.80, remaining 3.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and othe...
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
MiNK Therapeutics Inc (INKT) showcases promising clinical progress and strategic collaborations, while navigating financial hurdles and development risks.
Jennifer Buell: Thank you, Stefanie. For those new to MiNK Therapeutics, we are advancing a clinically validated allogeneic invariant natural killer T cell platform, one that is fundamentally differentiated in its ability to restore and coordinate immune function across diseases or even an immune failure. MiNK cells are now in Phase II clinical trials in patients with solid tumor cancers and autoimmune inflammatory conditions like GvHD and severe lung disease.
MiNK Therapeutics (NASDAQ:INKT) said it is advancing its off-the-shelf invariant natural killer T cell therapy platform into a randomized clinical program for severe acute lung injury and acute respiratory distress syndrome, while also reporting first-quarter 2026 financial results that management s
MiNK Therapeutics Inc (INKT) showcases robust financial growth and strategic clinical advancements, despite ongoing challenges.